Free Sales Ending Soon - 100% Valid RAC-GS Exam Dumps with 100 Questions
Verified RAC-GS dumps Q&As on your RAC Regulatory Affairs Certification Exam Questions Certain Success!
NEW QUESTION 50
According to the GHTF, which of the following is NOT an exemption rule when evaluating the decision to
report an adverse event?
- A. Adverse event caused by patient conditions
- B. Malfunction protection operated correctly
- C. Deficiency of a device found by the user prior to patient use
- D. Malfunction occurring before the end of service life of the medical device
Answer: A
NEW QUESTION 51
What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the
vendors comply with GMP requirements?
- A. Request documentation from the sub-contractor.
- B. Ask the vendor to take responsibility.
- C. Document and perform audits.
- D. Request an inspection from a regulatory authority.
Answer: C
NEW QUESTION 52
During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on
the part of the PI. What action should the sponsor take?
- A. Terminate the PI and inform the regulatory authorities.
- B. Send a letter of complaint to the Ethics Committee that approved the site.
- C. Increase the frequency of monitoring visits.
- D. Inform the institution that granted a medical license to the Pi.
Answer: A
NEW QUESTION 53
Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control
activities for a medical device?
- A. Fault tree analysis
- B. Fishbone analysis
- C. Quality by design analysis
- D. Failure modes, effects, and criticality analysis
Answer: D
NEW QUESTION 54
A clinical study of a drug is completed to support a marketing approval application. According to ICH, how
long should a sponsor retain the clinical study essential documents?
- A. For a minimum of 10 years after completion of the clinical study
- B. For at least two years after the last approval of an application in an ICH region
- C. Until the product has been discontinued from marketing in all ICH regions
- D. Three years after the last clinical study site was supplied with investigational drugs
Answer: B
NEW QUESTION 55
Under which of the following circumstances would a regulatory authority require a more detailed
premarket submission, a more rigorous audit, and/or the provision of more performance evaluation data
than would normally apply to an IVD device of that risk class?
- A. The device is an updated version of a compliant device from the same manufacturer and contains no
substantive change. - B. Internationally recognized standards are available to cover the main aspects of the device and have
been used by the manufacturer. - C. The device incorporates well-established technology that is already present in the market.
- D. The manufacturer's experience level with the type of IVD medical device is limited.
Answer: D
NEW QUESTION 56
Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during evaluation by a
reimbursement agency?
- A. "Has the product been approved for mor&4nan 10 years?"
- B. "Is the product an established gold standard?"
- C. "Is the product better than currently available alternatives?"
- D. "Is the product profitable for the manufacturer?"
Answer: C
NEW QUESTION 57
A regulatory affairs professional is asked to review and update regulatory affairs SOPs. Which aspect of
the SOP Is MOST important to consider?
- A. Relevance to regulations
- B. Revision history
- C. Scope and level of detail
- D. Expiration date
Answer: A
NEW QUESTION 58
After submission to the regulatory authority, a substantial error was found in the application. In order to
resolve this issue, what should be done FIRST?
- A. Inform upper management immediately.
- B. Contact the legal department and ask them how to proceed.
- C. Resubmit the entire package.
- D. Verify the procedure in the regulation for the corrections.
Answer: D
NEW QUESTION 59
During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The
intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.
What should be done in response to identifying the impurity?
- A. Perform a non-clinical qualification study, wait until the result is available, and then consider performing
an identification study. - B. Perform an identification study, wait until the result is available, and then consider performing a
non-clinical qualification study. - C. Perform both identification and non-clinical qualification studies concurrently.
- D. Perform either an identification study or a non-clinical qualification study.
Answer: B
NEW QUESTION 60
The manufacturer of an API was changed from Company X to Company Y during the late stage of a new
drug development. Despite differences in the manufacturing processes of the companies, both APIs meet
the current specifications. Which is the MOST appropriate information to include in the final submission
documents?
- A. The process information and analytical result of Company X API
- B. Information deemed appropriate by the regulatory authority
- C. The process information and analytical result of Company Y API
- D. The process information and the comparative analytical result of APIs from both companies
Answer: D
NEW QUESTION 61
Which of the following double-blind clinical trial designs would be MOST appropriate for a Phase III study
with a new product intended to treat an acute life-threatening disease with less than optimal available
therapy?
- A. Active-controlled
- B. Dose-ranging
- C. Placebo-controlled
- D. Cross-over
Answer: D
NEW QUESTION 62
A regulatory authority announces an inspection of a regulatory affairs professional's facility during a
holiday season when most of the staff Is not available. What is the MOST practical approach to this
dilemma?
- A. Insist that key personnel be available for the inspection.
- B. Inform the authority that the time is not suitable and request a new time
- C. Arrange for an inspection without all intended personnel.
- D. Negotiate with colleagues and the authority to find a better time.
Answer: D
NEW QUESTION 63
Which of the following criteria is MOST appropriate to define the animal species needed for the
pre-clinical toxicity testing of a biotechnology product?
- A. Immunochemical and functional tests
- B. Biological activity with species and/or tissue specificity
- C. Proposed product route and frequency of administration
- D. Proposed dose and volume of administration
Answer: B
NEW QUESTION 64
A company is developing a new product for the global market. A new international guideline will
recommend relevant studies in the pediatric population, and the guideline will be effective before the
approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this
guideline on the successful registration of the new product?
- A. The company should consult with relevant regulatory authorities to determine the potential impact on
the current registration plan. - B. The new guideline has no impact on the current registration plan, but the company must be prepared to
defend its decision. - C. The new guideline has no impact on the current registration plan since all relevant registration studies
are almost completed. - D. The company should initiate the required pediatric studies immediately to avoid costly delays to the
current registration plan.
Answer: A
NEW QUESTION 65
A manufacturer is involved in a recall event process for a plasma-derived product. From which stage
should the manufacturer be able to trace back the product?
- A. Product distribution
- B. Plasma pooling
- C. Individual plasma donation
- D. Plasma fractionation
Answer: A
NEW QUESTION 66
A company is currently marketing an implantable orthopedic medical device. The R&D department is
planning to change the material used for the implant. The R&D department states that the change does
not impact the safety and effectiveness of the product. What action should the regulatory affairs
professional take FIRST?
- A. Prepare regulatory submissions that detail the medical device's change in materials.
- B. No action is needed in this situation.
- C. Review the content of change and supporting data for the equivalency with the current material.
- D. Write a memo to file since the change does not impact product safety and effectiveness.
Answer: C
NEW QUESTION 67
Which of the following is MOST appropriate for the purpose of lot release of biologics?
- A. Inventory control
- B. Safety assurance
- C. Efficacy confirmation
- D. Quality verification
Answer: D
NEW QUESTION 68
Which of the following situations does NOT require rapid communication to regulatory authorities?
- A. A major safety finding from a newly completed animal carcinogenicity study
- B. A statistically significant increase in the number of deaths in an animal dose finding study
- C. A lack of efficacy with a medicinal product used in treating a life-threatening disease
- D. A clinically important increase in the rate of occurrence of an "expected." but serious ADR
Answer: D
NEW QUESTION 69
The API used for an approved drug product conforms to international monograph specifications and local
pharmacopeia; however, the international monograph specifications of the API will be changing soon.
Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Confirm that the international monograph change is not related to local pharmacopeia.
- B. Prepare the international monograph change submission first and then prepare the local change when
required. - C. Analyze the impact of the international monograph change on the local pharmacopeia.
- D. Transfer the notice of the upcoming international monograph change to QA for further processing.
Answer: D
NEW QUESTION 70
What are the MOST important elements that global regulatory agencies want to know before approving a
new product for sale in their countries?
- A. Safety and failure risk
- B. Quality and failure risk
- C. Quality and effectiveness
- D. Safety and effectiveness
Answer: D
NEW QUESTION 71
A request was received from a regulatory authority asking the company to conduct product testing in
compliance with a newly issued regulation.
What should be done. What action should the company take FIRST?
- A. Send a letter back to the regulatory authority indicating why the regulation does not apply to the
product. - B. Consult with colleagues about the request.
- C. Contact the regulatory authority that issued this request and discuss the requirement.
- D. Initiate testing immediately to ensure compliance.
Answer: C
NEW QUESTION 72
Which of the following BEST describes the process of post-marketing surveillance for healthcare
products?
- A. Systematic procedure to review published scientific journals
- B. Systematic procedure to review experiences with the products in use
- C. Vigilance procedure to notify the regulatory authorities about serious incidents
- D. Vigilance procedure to ensure the full traceability of the products
Answer: D
NEW QUESTION 73
......
RAC-GS Exam Dumps - 100% Marks In RAC-GS Exam: https://www.actual4dump.com/RAPS/RAC-GS-actualtests-dumps.html